Flecainide-Associated Cardiogenic Shock in a Patient with Atrial Fibrillation
Flecainide is a frequently used antiarrhythmic drug, recommended by current guidelines as a first-line treatment option for restoring and maintaining sinus rhythm in patients with atrial fibrillation and no significant structural heart disease. In overdose, it can induce severe cardiogenic shock. Ca...
Saved in:
| Main Authors: | Erind Gjermeni, Andreas Bollmann, Gerhard Hindricks, Andreas Müssigbrodt |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-01-01
|
| Series: | Case Reports in Cardiology |
| Online Access: | http://dx.doi.org/10.1155/2019/4820652 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Effectiveness and safety of vernakalant vs flecainide for cardioversion of atrial fibrillation in the emergency department: the VERITA study
by: Giuseppe Dominijanni, et al.
Published: (2025-08-01) -
Current treatment of cardiogenic shock
by: Gligić Branko, et al.
Published: (2003-01-01) -
Myocardial Recovery in Cardiogenic Shock
by: Kevin John, et al.
Published: (2024-08-01) -
The Contemporary Cardiogenic Shock ‘Playbook’
by: Alexander G Truesdell
Published: (2021-11-01) -
Intensive Care Management of the Cardiogenic Shock Patient
by: Shahana Uddin, et al.
Published: (2022-07-01)